- Home
- JFU vs ATHA Comparison
JFU vs ATHA Comparison
Compare JFU & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- ATHA
- Stock Information
- Founded
- JFU 2006
- ATHA 2011
- Country
- JFU China
- ATHA United States
- Employees
- JFU N/A
- ATHA N/A
- Industry
- JFU Finance: Consumer Services
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- JFU Finance
- ATHA Health Care
- Exchange
- JFU Nasdaq
- ATHA Nasdaq
- Market Cap
- JFU 17.8M
- ATHA 21.0M
- IPO Year
- JFU 2019
- ATHA 2020
- Fundamental
- Price
- JFU $1.58
- ATHA $0.51
- Analyst Decision
- JFU
- ATHA Buy
- Analyst Count
- JFU 0
- ATHA 4
- Target Price
- JFU N/A
- ATHA $11.25
- AVG Volume (30 Days)
- JFU 5.0K
- ATHA 213.9K
- Earning Date
- JFU 01-01-0001
- ATHA 02-20-2025
- Dividend Yield
- JFU N/A
- ATHA N/A
- EPS Growth
- JFU N/A
- ATHA N/A
- EPS
- JFU 0.09
- ATHA N/A
- Revenue
- JFU $40,614,155.00
- ATHA N/A
- Revenue This Year
- JFU N/A
- ATHA N/A
- Revenue Next Year
- JFU N/A
- ATHA N/A
- P/E Ratio
- JFU $16.63
- ATHA N/A
- Revenue Growth
- JFU N/A
- ATHA N/A
- 52 Week Low
- JFU $1.13
- ATHA $0.41
- 52 Week High
- JFU $3.75
- ATHA $4.30
- Technical
- Relative Strength Index (RSI)
- JFU 54.21
- ATHA 35.67
- Support Level
- JFU $1.47
- ATHA $0.48
- Resistance Level
- JFU $1.59
- ATHA $0.57
- Average True Range (ATR)
- JFU 0.04
- ATHA 0.04
- MACD
- JFU 0.01
- ATHA -0.00
- Stochastic Oscillator
- JFU 80.00
- ATHA 10.64
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.